Autolus scores $80 mln Series C

London-based Autolus, a biopharmaceutical company focused on developing and commercializing T-cell therapies, has raised $80 million in Series C funding. The investors included Arix Bioscience plc, Cormorant Asset Management, Nextech Invest, Syncona and Woodford Investment Management.

North AmericaUSBriefs